Bartholin's gland carcinoma-the diagnostic and management challenges of a rare malignancy-a case report and review of current literature.
Bartholin’s gland carcinoma (BGC)
case report
gynaecological-oncology
surgery
vulval cancer
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
30 Jan 2023
30 Jan 2023
Historique:
received:
08
03
2022
accepted:
02
12
2022
entrez:
10
2
2023
pubmed:
11
2
2023
medline:
11
2
2023
Statut:
ppublish
Résumé
Bartholin's gland carcinoma (BGC) accounts for approximately 5% of all vulval malignancies-making it an extremely rare malignancy of the female genital tract. It commonly manifests as a painless unilateral mass, near the introitus. BGC more commonly occurs in post-menopausal women. Unfortunately, over half of cases are associated with a missed or delayed diagnosis as it is often mistaken for a Bartholin's gland cyst or abscess. These tumours have a predilection for local and perineural invasion. Magnetic resonance imaging (MRI) is the imaging modality of choice for suspected Bartholin's tumour. Although no current guidance dedicated to the management of BGC exists, the majority of cases are treated by primary excision and bilateral groin node dissection (GND). Chemoradiotherapy has a role in both the adjuvant and palliative setting. BGC are typically associated with more advanced disease at presentation, higher rates of recurrence and poorer prognosis than other vulval cancer sub-types. We share a case report of primary BGC-supported by high-quality radiological and surgical images; and further supplemented by a detailed review of current literature. We aim to generate improved clinician awareness of this rare pathology, highlighting the need for vigilance to avoid misdiagnosis and subsequent treatment delay; as well as contribute towards generating consensus on the approach to management of this gynaecological malignancy.
Sections du résumé
Background
UNASSIGNED
Bartholin's gland carcinoma (BGC) accounts for approximately 5% of all vulval malignancies-making it an extremely rare malignancy of the female genital tract. It commonly manifests as a painless unilateral mass, near the introitus. BGC more commonly occurs in post-menopausal women. Unfortunately, over half of cases are associated with a missed or delayed diagnosis as it is often mistaken for a Bartholin's gland cyst or abscess. These tumours have a predilection for local and perineural invasion. Magnetic resonance imaging (MRI) is the imaging modality of choice for suspected Bartholin's tumour. Although no current guidance dedicated to the management of BGC exists, the majority of cases are treated by primary excision and bilateral groin node dissection (GND). Chemoradiotherapy has a role in both the adjuvant and palliative setting. BGC are typically associated with more advanced disease at presentation, higher rates of recurrence and poorer prognosis than other vulval cancer sub-types.
Case Description
UNASSIGNED
We share a case report of primary BGC-supported by high-quality radiological and surgical images; and further supplemented by a detailed review of current literature.
Conclusions
UNASSIGNED
We aim to generate improved clinician awareness of this rare pathology, highlighting the need for vigilance to avoid misdiagnosis and subsequent treatment delay; as well as contribute towards generating consensus on the approach to management of this gynaecological malignancy.
Identifiants
pubmed: 36760371
doi: 10.21037/tcr-22-612
pii: tcr-12-01-201
pmc: PMC9906066
doi:
Types de publication
Case Reports
Langues
eng
Pagination
201-208Informations de copyright
2023 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-612/coif). HSM serves as an unpaid editorial board member of Translational Cancer Research from September 2021 to August 2023. The other authors have no conflicts of interest to declare.
Références
Gynecol Oncol Rep. 2018 Nov 16;27:15-18
pubmed: 30555885
Gynecol Oncol. 1989 Aug;34(2):145-7
pubmed: 2546874
Obstet Gynecol. 1986 Jun;67(6):794-801
pubmed: 3010205
Taiwan J Obstet Gynecol. 2012 Mar;51(1):119-20
pubmed: 22482984
Surg Oncol. 2013 Jun;22(2):117-22
pubmed: 23499140
Turk J Obstet Gynecol. 2020 Dec;17(4):310-313
pubmed: 33343978
Crit Rev Oncol Hematol. 2017 Sep;117:1-11
pubmed: 28807231
Eur J Gynaecol Oncol. 2011;32(5):567-72
pubmed: 22053678
Gynecol Oncol. 2001 Aug;82(2):247-51
pubmed: 11531274
Oncol Lett. 2014 Aug;8(2):849-851
pubmed: 25013508
Int J Gynecol Cancer. 2016 May;26(4):785-9
pubmed: 26844611
Obstet Gynecol. 1982 Sep;60(3):361-8
pubmed: 7121917
Am J Pathol. 1993 Mar;142(3):925-33
pubmed: 8384409
Gynecol Oncol. 2002 Nov;87(2):210-2
pubmed: 12477454
Best Pract Res Clin Obstet Gynaecol. 2003 Aug;17(4):609-33
pubmed: 12965135
Gynecol Oncol. 1999 Nov;75(2):305-7
pubmed: 10525393
Int J Gynecol Cancer. 2007 May-Jun;17(3):661-7
pubmed: 17504379
Obstet Gynecol. 1972 Apr;39(4):489-94
pubmed: 4336255
Iran J Med Sci. 2014 Nov;39(6):580-3
pubmed: 25429183